Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (F:RIG2) — Market Cap & Net Worth
Market Cap & Net Worth: Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (RIG2)
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt (F:RIG2) has a market capitalization of $6.56 Billion (€5.61 Billion) as of October 14, 2026. Listed on the F stock exchange, this Germany-based company holds position #2971 globally and #590 in its home market, demonstrating a 1.70% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's stock price €33.56 by its total outstanding shares 182387869 (182.39 Million).
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Market Cap History: 2015 to 2026
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's market capitalization history from 2015 to 2026. Data shows growth from $3.70 Billion to $7.16 Billion (7.62% CAGR). Check RIG2 share price today for real-time trading data and today's change.
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Richter Gedeon Vegyészeti Gyár Nyilvános cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.01x
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.02x
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's market cap is 0.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.15 Billion | $389.69 Billion | $66.20 Billion | 0.01x | 0.06x |
| 2017 | $4.60 Billion | $444.36 Billion | $8.88 Billion | 0.01x | 0.52x |
| 2018 | $3.56 Billion | $445.48 Billion | $35.35 Billion | 0.01x | 0.10x |
| 2019 | $4.05 Billion | $507.79 Billion | $47.13 Billion | 0.01x | 0.09x |
| 2020 | $4.38 Billion | $566.78 Billion | $104.68 Billion | 0.01x | 0.04x |
| 2021 | $4.95 Billion | $630.60 Billion | $139.63 Billion | 0.01x | 0.04x |
| 2022 | $4.33 Billion | $802.75 Billion | $155.58 Billion | 0.01x | 0.03x |
| 2023 | $4.81 Billion | $805.16 Billion | $158.85 Billion | 0.01x | 0.03x |
| 2024 | $5.32 Billion | $857.54 Billion | $239.24 Billion | 0.01x | 0.02x |
| 2025 | $5.54 Billion | $928.96 Billion | $232.34 Billion | 0.01x | 0.02x |
Competitor Companies of RIG2 by Market Capitalization
Companies near Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt in the global market cap rankings as of October 14, 2026. See Richter Gedeon Vegyészeti Gyár Nyilvános balance sheet independence to understand what proportion of total assets are financed by equity.
Key companies related to Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #528 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #580 globally with a market cap of $46.89 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #643 globally with a market cap of $42.48 Billion USD ( CN¥290.31 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #528 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #580 | GALDERMA GROUP AG | NYSE:GALDY | $46.89 Billion | $40.22 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.50 |
| #643 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $42.48 Billion | CN¥45.51 |
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Historical Marketcap From 2015 to 2026
Between 2015 and today, Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's market cap moved from $3.70 Billion to $ 7.16 Billion, with a yearly change of 7.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €7.16 Billion | +29.18% |
| 2025 | €5.54 Billion | +4.17% |
| 2024 | €5.32 Billion | +10.55% |
| 2023 | €4.81 Billion | +11.13% |
| 2022 | €4.33 Billion | -12.58% |
| 2021 | €4.95 Billion | +13.16% |
| 2020 | €4.38 Billion | +8.00% |
| 2019 | €4.05 Billion | +13.91% |
| 2018 | €3.56 Billion | -22.63% |
| 2017 | €4.60 Billion | +10.88% |
| 2016 | €4.15 Billion | +11.98% |
| 2015 | €3.70 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 14th, 2026 the market cap of Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.56 Billion USD |
| MoneyControl | $6.56 Billion USD |
| MarketWatch | $6.56 Billion USD |
| marketcap.company | $6.56 Billion USD |
| Reuters | $6.56 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chron… Read more